Cas:10172-35-7 2-Bromo-4-methoxy-6-nitroaniline manufacturer & supplier

Chemical Name:2-Bromo-4-methoxy-6-nitroaniline

CAS.NO:10172-35-7

Synonyms:4-Amino-3-brom-5-nitro-anisol;Benzenamine, 2-bromo-4-methoxy-6-nitro-;2-Bromo-4-methoxy-6-nitroaniline

Molecular Formula:C₇H₇BrN₂O₃

Molecular Weight:247.046

HS Code:2922299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:352.1±37.0 °C at 760 mmHg

Density:1.7±0.1 g/cm3

Index of Refraction:1.634

PSA:81.07000

Exact Mass:245.964005

LogP:3.12

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Amino-3-brom-5-nitro-anisol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-4-methoxy-6-nitroaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Amino-3-brom-5-nitro-anisol Use and application,2-Bromo-4-methoxy-6-nitroaniline technical grade,usp/ep/jp grade.

Related News: In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired. 2-Bromo-4-methoxy-6-nitroaniline manufacturer By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. 2-Bromo-4-methoxy-6-nitroaniline supplier In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired. 2-Bromo-4-methoxy-6-nitroaniline vendor While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. 2-Bromo-4-methoxy-6-nitroaniline factory At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.